Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis This randomized clinical trial investigates the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Loading next page...
 
/lp/american-medical-association/efficacy-and-safety-of-abrocitinib-in-patients-with-moderate-to-severe-ZBePDz31eh

References (42)

Publisher
American Medical Association
Copyright
Copyright 2020 Silverberg JI et al. JAMA Dermatology.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2020.1406
Publisher site
See Article on Publisher Site

Abstract

This randomized clinical trial investigates the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis.

Journal

JAMA DermatologyAmerican Medical Association

Published: Aug 3, 2020

There are no references for this article.